Leukotriene receptor antagonists--risks and benefits for use in paediatric asthma (Q35779312)

10 August 2017

1 reference

title

Leukotriene receptor antagonists--risks and benefits for use in paediatric asthma (English)

1 reference

10 August 2017

Jonathan E Spahr

1

1 reference

10 August 2017

Marzena E Krawiec

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Expert Opinion on Drug Safety

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

173-185

1 reference

10 August 2017

cites work

New aspects of asthma

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Leukotriene C: a slow-reacting substance from murine mastocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Characterization of the human cysteinyl leukotriene CysLT1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Characterization of the human cysteinyl leukotriene 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

21 January 2018

Late asthmatic responses

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Effects of montelukast and budesonide on airway responses and airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Effectiveness and tolerability of zafirlukast for the treatment of asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Pharmacogenetics of treatment with leukotriene modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Effects of oral montelukast on airway function in acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

A randomized controlled trial of intravenous montelukast in acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

"Real-world" effectiveness of daily controller medicine in children with mild persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

A drug interaction between zafirlukast and theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Churg-Strauss Syndrome in Patients Receiving Montelukast as Treatment for Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Churg-Strauss syndrome associated with montelukast therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Leukotriene antagonists and the Churg-Strauss syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Sputum Cysteinyl Leukotrienes Increase 24 Hours after Allergen Inhalation in Atopic Asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

Leukotrienes are potent constrictors of human bronchi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.173

21 January 2018

Identifiers

DOI

10.1517/14740338.3.3.173

1 reference

10 August 2017

1 reference